We performed immunohistochemistry (IHC) to detect SGOL2 expression among 91 prostate cancer patients, which indicated that higher-grade prostate cancer expressed higher SGOL2 expression (Figure 1D). This evidence concerns the gene SGO2 and prostate cancer.